Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) has received a consensus rating of "Moderate Buy" from the fourteen analysts that are currently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $24.50.

Several equities research analysts have commented on the stock. JMP Securities restated a "market outperform" rating and issued a $28.00 price target on shares of Kura Oncology in a research note on Wednesday, June 4th. Wall Street Zen cut shares of Kura Oncology from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. Cantor Fitzgerald reiterated an "overweight" rating on shares of Kura Oncology in a report on Thursday, June 26th. HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of Kura Oncology in a report on Monday, April 28th. Finally, Wedbush reiterated an "outperform" rating and issued a $36.00 price objective on shares of Kura Oncology in a report on Friday, June 20th.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. BVF Inc. IL grew its position in Kura Oncology by 202.0% during the 1st quarter. BVF Inc. IL now owns 7,754,129 shares of the company's stock worth $51,177,000 after purchasing an additional 5,186,660 shares in the last quarter. RA Capital Management L.P. purchased a new position in Kura Oncology during the 4th quarter worth approximately $38,769,000. Millennium Management LLC grew its position in Kura Oncology by 180.1% during the 4th quarter. Millennium Management LLC now owns 2,367,148 shares of the company's stock worth $20,618,000 after purchasing an additional 1,521,954 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in Kura Oncology during the 4th quarter worth approximately $8,518,000. Finally, Marshall Wace LLP purchased a new position in Kura Oncology during the 4th quarter worth approximately $8,265,000.

Kura Oncology Price Performance

Shares of NASDAQ:KURA opened at $6.60 on Friday. The firm's 50 day moving average is $6.10 and its two-hundred day moving average is $6.87. Kura Oncology has a 52 week low of $5.41 and a 52 week high of $22.07. The firm has a market capitalization of $571.36 million, a P/E ratio of -3.14 and a beta of 0.40. The company has a current ratio of 8.07, a quick ratio of 8.07 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The business had revenue of $14.11 million for the quarter, compared to the consensus estimate of $39.08 million. Analysts anticipate that Kura Oncology will post -2.44 earnings per share for the current year.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.